Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005: Demand, supply and seasonality

Table 1 MCV4 uptake during 2005 among 11-16 year old adolescents by MCO and age group

MCO	Local or state MCV4 Legislation^§	MCV4 shortage during 2005^§	Study Population	All adolescents Number (%) Vaccinated		Percent Vaccinated by Age Group
						11-12	14-15	13+16 (Ref)
A	Yes^†	No	19724	3680	(18.7)	33.7*	13.8*	9.6
B	No	No	31404	9518	(30.3)	31.9*	32.0*	27.0
C	No	Yes	13456	1832	(13.6)	15.2*	13.4	12.3
D	Unknown^‡	Yes	261544	17934	(6.9)	6.4	7.7*	6.4
E	Unknown^‡	Yes	297761	31308	(10.5)	13.9*	10.3*	7.5
All MCOs	--	--	623889	64272	(10.3)	12.3*	10.5*	8.2

MCV4 - Meningococcal conjugate vaccine
MCO - Managed care organization
^§Based on self-report by principal investigator at each MCO
^†MCO is located in a state with legislation requiring meningococcal vaccination for adolescents in residential schools and postsecondary institutions that provide housing for students.
^‡MCO did not provide a response; however, the state(s) these MCOs are located in did(do) not have any meningococcal vaccination legislation[24].
*p < 0.001 when compared to 13+16 year group

ISSN: 1471-2334